Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform

• Κύριοι συγγραφείς: Lisa D. MacDonald (Συγγραφέας), Alecia MacKay (Συγγραφέας), Valarmathy Kaliaperumal (Συγγραφέας), Genevieve Weir (Συγγραφέας), Andrea Penwell (Συγγραφέας), Rajkannan Rajagopalan (Συγγραφέας), Joanne M. Langley (Συγγραφέας), Scott Halperin (Συγγραφέας), Marc Mansour (Συγγραφέας), Marianne M. Stanford (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Peptide antigens are combined with an adjuvant in order to increase immunogenicity in vivo. The immunogenicity and safety of a RSV vaccine formulated in a novel oil-based platform, DepoVax™ (DPX), was compared to an alum formulation. A peptide B cell epitope derived from RSV small hydrophobic ectodo...